214 results
P
I/C
l, o, w, -, l, e, v, e, l, , a, r, s, e, n, i, c, , (, A, s, ), , c, o, n, c, e, n, t, r, a, t, i, o, n, , i, n, , d, r, i, n, k, i, n, g, , w, a, t, e, r, d, r, i, n, k, i, n, g, , w, a, t, e, r, , A, s, , c, o, n, c, e, n, t, r, a, t, i, o, n, s, , l, o, w, e, r, , t, h, a, n, , t, h, e, , W, H, O, , p, r, o, v, i, s, i, o, n, a, l, , g, u, i, d, e, l, i, n, e, , v, a, l, u, e, , (, 1, 0, , µ, g, /, L, )
O
p, o, o, l, e, d, , a, s, s, o, c, i, a, t, i, o, n, , b, e, t, w, e, e, n, , t, h, e, , r, e, l, a, t, i, v, e, , r, i, s, k, , o, f, , e, a, c, h, , c, a, r, d, i, o, v, a, s, c, u, l, a, r, , d, i, s, e, a, s, e, , (, C, V, D, ), , e, n, d, p, o, i, n, t, , a, n, d, , l, o, w, -, l, e, v, e, l, , A, s, , c, o, n, c, e, n, t, r, a, t, i, o, n, , i, n, , d, r, i, n, k, i, n, g, , w, a, t, e, r
P
critically ill patients
I/C
peri-intubation major adverse events, no peri-intubation major adverse events
O
hypoxia, hypotension/cardiovascular collapse, cardiac arrest
P
health professionals (HPs)
I/C
formal R/S-training, physicians, nurses
O
belief in influence of R/S on patients' health, prevalence of formal R/S-training
P
peri-implant pathology
I/C
probiotics, conventional treatment or placebo
O
response to treatment
P
shoulder surgery patients
I/C
peri-articular infiltration analgesia, control or interscalene brachial plexus block
O
cumulative oral morphine equivalent consumption during the first 24 h postoperatively, rest pain scores up to 48 h, risk of side-effects, duration of post-anaesthetic care unit and hospital stay
P
patients with peri-implant diseases
I/C
nonsurgical treatment combined with probiotic Lactobacillus, placebo agent
O
probing pocket depth (PPD), bleeding on probing, plaque index
P
nurse-led peri-discharge interventions
I/C
usual care, randomized controlled trials
O
all-cause 30-day hospital readmissions
P
patients undergoing abdominal surgery under general anesthesia
I/C
forced air warming (FAW) intervention, insufficient methods of forced air warming
O
peri-operative hypothermia prevention
P
metastatic or recurrent gastric cancer patients
I/C
capecitabine-based chemotherapy, S-1-based chemotherapy
O
objective response rate, 6-, 12-, and 18-month progression-free survival, 1-, 2-, and 3-year overall survival, adverse events (hand-foot syndrome, neutropenia)
P
GSNO
I/C
S-Nitrosoglutathione, Placebo
O
Infarct size, Neurological behavior scales, Embolic signals